$RAFA Under the joint venture RAFARMA will combine the expertise of Vaccines Labs RAFARMA with its PJSC Kraspharma R. & D. Biocogency Laboratories Inc. 

RAFARMA plan includes the investment of approximately USD $1,000,000,000 (USA One Billion Dollars) for the joint venture; whereas VACCINE LABS will provide government joint venture, partnership, regulation, licenses, and incentives for the project.

RAFARMA shall subscribe to 51% of JV-company in the form of preference shares, subject to the approval of such ownership by the Indonesian government The production capacity of the plant is designed for 500-600 million doses , covering the needs of the entire territory of Indonesia and the ASIAN countries

Published by Vacine Labs